<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>Light Lunch &amp; Registration</td>
</tr>
<tr>
<td>1:30</td>
<td><strong>HBV Forum 5 Opening</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Forum Moderator:</strong> Veronica Miller, <em>The Forum for Collaborative Research</em></td>
</tr>
<tr>
<td>1:30</td>
<td><strong>Welcome and Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>Ryan Anderson, <em>The Forum for Collaborative Research</em></td>
</tr>
<tr>
<td></td>
<td>Harry Janssen, Toronto Centre for Liver Disease, University Health Network</td>
</tr>
<tr>
<td></td>
<td>Anuj Gaggar, Gilead</td>
</tr>
<tr>
<td>1:40</td>
<td><strong>Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Session Co-Moderator:</strong> Marion Peters, University of California, San Francisco</td>
</tr>
<tr>
<td>1:45</td>
<td>HDV Therapy - Relevant Recent Findings and Suggested Endpoints</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Glenn, Stanford University Medical Center</td>
</tr>
<tr>
<td>1:55</td>
<td>Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B</td>
</tr>
<tr>
<td></td>
<td>Stephan Urban, University Hospital Heidelberg</td>
</tr>
<tr>
<td>2:05</td>
<td><strong>Clinical Challenges in the Development of HDV Infection</strong></td>
</tr>
<tr>
<td></td>
<td>Heiner Wedemeyer, Essen University Hospital</td>
</tr>
<tr>
<td>2:15</td>
<td><strong>Panel Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Eric Donaldson, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Glenn, Stanford University Medical Center</td>
</tr>
<tr>
<td></td>
<td>Stephan Urban, University Hospital Heidelberg</td>
</tr>
<tr>
<td></td>
<td>Heiner Wedemeyer, Essen University Hospital</td>
</tr>
<tr>
<td></td>
<td>Gabriel Westman, Swedish Medical Products Agency</td>
</tr>
<tr>
<td>3:00</td>
<td><strong>Session II: HBV Forum Working Group Updates</strong></td>
</tr>
<tr>
<td>3:00</td>
<td>Surrogate Endpoints Working Group Update</td>
</tr>
<tr>
<td></td>
<td>Marion Peters, University of California, San Francisco</td>
</tr>
<tr>
<td>3:10</td>
<td>Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis</td>
</tr>
<tr>
<td></td>
<td>Ryan Anderson, <em>The Forum for Collaborative Research</em></td>
</tr>
<tr>
<td>3:30</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>4:00</td>
<td>Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel</td>
</tr>
<tr>
<td></td>
<td>Maria Beumont-Mauviel, Janssen Pharmaceuticals</td>
</tr>
<tr>
<td>4:20</td>
<td><strong>Immune Monitoring Working Group Update</strong></td>
</tr>
<tr>
<td></td>
<td>Sara Ferrando-Martinez, AstraZeneca</td>
</tr>
<tr>
<td>4:40</td>
<td><strong>Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Session Co-Moderator:</strong> Bruce Given, Arrowhead Pharmaceuticals</td>
</tr>
<tr>
<td>4:45</td>
<td>Expert Perspectives, Relevant Recent Findings, and Panel Discussion</td>
</tr>
<tr>
<td></td>
<td>Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BiArM)</td>
</tr>
<tr>
<td></td>
<td>Russell Fleischer, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td></td>
<td>Harry Janssen, Toronto Centre for Liver Disease, University Health Network</td>
</tr>
<tr>
<td></td>
<td>Su Wang, World Hepatitis Alliance, Hepatitis B Foundation</td>
</tr>
<tr>
<td>5:55</td>
<td><strong>Wrap Up</strong></td>
</tr>
<tr>
<td></td>
<td>Veronica Miller, <em>The Forum for Collaborative Research</em></td>
</tr>
<tr>
<td>6:00</td>
<td><strong>Adjourn and Evening Networking Reception</strong></td>
</tr>
</tbody>
</table>